image
Pacific Biosciences of California, Inc. PACB
Healthcare - Medical - Devices - NASDAQ - US
Watchlist
$ 1.23
3.36 %
$ 366 M
Market Cap
-0.77
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one PACB stock under the worst case scenario is HIDDEN Compared to the current market price of 1.23 USD, Pacific Biosciences of California, Inc. is HIDDEN

PACB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one PACB stock under the base case scenario is HIDDEN Compared to the current market price of 1.23 USD, Pacific Biosciences of California, Inc. is HIDDEN

PACB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one PACB stock under the best case scenario is HIDDEN Compared to the current market price of 1.23 USD, Pacific Biosciences of California, Inc. is HIDDEN

PACB Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PACB

image
1M -8%
6M -33%
1Y -172%
3Y -590%
5Y -144%
All
$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
154 M REVENUE
-23.19%
Growth Rates
1Year -23.19%
3Years 5.67%
5Years 11.12%
7Years 7.40%
10Years 9.78%
-356 M OPERATING INCOME
-6.55%
Growth Rates
1Year -6.55%
3Years -26.00%
5Years -28.80%
7Years -21.77%
10Years -18.95%
-310 M NET INCOME
-1.02%
Growth Rates
1Year -1.02%
3Years -19.58%
5Years -29.79%
7Years -18.91%
10Years -16.70%
-206 M OPERATING CASH FLOW
20.49%
Growth Rates
1Year 20.49%
3Years -22.83%
5Years -21.35%
7Years -17.28%
10Years -14.88%
124 M INVESTING CASH FLOW
2593.40%
Growth Rates
1Year 2593.40%
3Years 29.72%
5Years 14.85%
7Years 87.69%
10Years 20.28%
-43 M FINANCING CASH FLOW
-39.48%
Growth Rates
1Year -39.48%
3Years -1.21%
5Years -21.24%
7Years -7.18%
10Years -7.30%
39.2 M REVENUE
-1.86%
Growth Rates
1Year -23.19%
3Years 5.67%
5Years 11.12%
7Years 7.40%
10Years 9.78%
-123 M OPERATING INCOME
-107.00%
Growth Rates
1Year -6.55%
3Years -26.00%
5Years -28.80%
7Years -21.77%
10Years -18.95%
2.37 M NET INCOME
103.90%
Growth Rates
1Year -1.02%
3Years -19.58%
5Years -29.79%
7Years -18.91%
10Years -16.70%
-30.6 M OPERATING CASH FLOW
32.58%
Growth Rates
1Year 20.49%
3Years -22.83%
5Years -21.35%
7Years -17.28%
10Years -14.88%
58.2 M INVESTING CASH FLOW
152.50%
Growth Rates
1Year 2593.40%
3Years 29.72%
5Years 14.85%
7Years 87.69%
10Years 20.28%
-50.2 M FINANCING CASH FLOW
-6182.27%
Growth Rates
1Year -39.48%
3Years -1.21%
5Years -21.24%
7Years -7.18%
10Years -7.30%
Balance Sheet Pacific Biosciences of California, Inc.
image
Current Assets 496 M
Cash & Short-Term Investments 390 M
Receivables 27.5 M
Other Current Assets 78.2 M
Non-Current Assets 765 M
Long-Term Investments 0
PP&E 46.6 M
Other Non-Current Assets 718 M
30.94 %6.21 %3.70 %56.98 %Total Assets$1.3b
Current Liabilities 66.3 M
Accounts Payable 16.6 M
Short-Term Debt 10 M
Other Current Liabilities 39.7 M
Non-Current Liabilities 688 M
Long-Term Debt 662 M
Other Non-Current Liabilities 25.1 M
5.26 %87.87 %3.34 %Total Liabilities$753.9m
EFFICIENCY
Earnings Waterfall Pacific Biosciences of California, Inc.
image
Revenue 154 M
Cost Of Revenue 117 M
Gross Profit 37.3 M
Operating Expenses 394 M
Operating Income -356 M
Other Expenses -46.5 M
Net Income -310 M
200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)154m(117m)37m(394m)(356m)47m(310m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
24.21% GROSS MARGIN
24.21%
Averages
1Year 24.21%
3Years 29.58%
5Years 35.02%
7Years 35.01%
10Years 38.85%
-231.40% OPERATING MARGIN
-231.40%
Averages
1Year -231.40%
3Years -211.92%
5Years -180.92%
7Years -163.38%
10Years -134.96%
-201.18% NET MARGIN
-201.18%
Averages
1Year -201.18%
3Years -195.19%
5Years -137.43%
7Years -129.03%
10Years -111.80%
-61.16% ROE
-61.16%
Averages
1Year -61.16%
3Years -52.55%
5Years -34.36%
7Years -57.63%
10Years -64.14%
-24.58% ROA
-24.58%
Averages
1Year -24.58%
3Years -19.65%
5Years -12.18%
7Years -24.81%
10Years -31.58%
-29.63% ROIC
-29.63%
Averages
1Year -29.63%
3Years -21.96%
5Years -21.08%
7Years -33.64%
10Years -40.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pacific Biosciences of California, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -310 M
Depreciation & Amortization 41.2 M
Capital Expenditures -6.19 M
Stock-Based Compensation 71 M
Change in Working Capital 0
Others -8.22 M
Free Cash Flow -212 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pacific Biosciences of California, Inc.
image
Wall Street analysts predict an average 1-year price target for PACB of $3 , with forecasts ranging from a low of $2 to a high of $4 .
PACB Lowest Price Target Wall Street Target
2 USD 62.60%
PACB Average Price Target Wall Street Target
3 USD 143.90%
PACB Highest Price Target Wall Street Target
4 USD 225.20%
Price
Max Price Target
Min Price Target
Average Price Target
44443333222211May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Pacific Biosciences of California, Inc.
image
Sold
0-3 MONTHS
824 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
313 K USD 4
9-12 MONTHS
10.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close. zacks.com - 2 weeks ago
Here's Why You Should Retain PacBio Stock in Your Portfolio Now PACB continues to deliver growth from its unique technologies amid macroeconomic concerns. zacks.com - 2 weeks ago
Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes. globenewswire.com - 2 weeks ago
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day. zacks.com - 3 weeks ago
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock seekingalpha.com - 1 month ago
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. globenewswire.com - 1 month ago
PacBio Grants Equity Incentive Award to New Employee MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4). globenewswire.com - 1 month ago
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments. zacks.com - 1 month ago
Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - President and CEO Michele Farmer - Chief Accounting Officer Conference Call Participants Tycho Peterson - Jefferies Kyle Mikson - Canaccord Dan Brennan - TD Cowen Doug Schenkel - Wolfe Research Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Sung Ji Nam - Scotia Bank Mason Carrico - Stephens Operator Good day. And welcome to the PacBio Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago. zacks.com - 1 month ago
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close. zacks.com - 2 months ago
8. Profile Summary

Pacific Biosciences of California, Inc. PACB

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 366 M
Dividend Yield 0.00%
Description Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Contact 1305 O’Brien Drive, Menlo Park, CA, 94025 https://www.pacb.com
IPO Date Oct. 27, 2010
Employees 575
Officers Mr. Christian O. Henry M.B.A. President, Chief Executive Officer, Interim Chief Financial Officer & Director Mr. Mark Van Oene Ph.D. Chief Operating Officer Ms. Michele Farmer CPA Vice President & Chief Accounting Officer Dr. Brett Atkins J.D., Ph.D. General Counsel & Corporate Secretary Ms. Natalie Welch Chief People Officer Mr. David Ruggiero Global Head of Sales & Service Dr. Stephen Turner Ph.D. Co-Founder